
Incyte rose 7.9% from $106.24 to $114.63, ahead of the S&P 500's +3.2%. Its worst day was Feb 10 (−8.2%), and its low came Mar 27 at $90.30.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Mizuho moved Incyte from Neutral to Outperform and lifted its price target from $90.00 to $121.00; shares fell 5.7%.
−5.7% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Incyte shares rose 5.5%, while the S&P 500 rose 0.9%.
+5.5% · S&P 500 +0.9%
EPS of $1.80 missed the $1.83 estimate on $1.5B revenue (est. $1.4B).
−8.2%, the year's worst day · S&P 500 −0.3%
Incyte closed at its lowest level of the year, 15.0% below where the year started.
−2.1% · S&P 500 −1.7%
EPS of $1.81 beat the $1.31 estimate on $1.3B revenue (est. $1.2B); FY revenue guidance of $4.8B–$4.9B against the $5.6B consensus.
+2.1% · S&P 500 −0.5%
Incyte shares rose 6.2%, while the S&P 500 fell 0.7%.
+6.2% · S&P 500 −0.7%
- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP- U.S.
−6.0% · S&P 500 +1.8%
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have
+5.8% · S&P 500 −0.7%
EPS of $3.09 beat the $1.84 estimate on $1.7B revenue (est. $1.4B); FY revenue guidance of $5.1B–$5.3B against the $5.6B consensus.
+9.3%, the year's best day, on 6M shares, the year's heaviest volume · S&P 500 +0.2%
EPS of $-3.60 beat the $-3.95 estimate on $1.6B revenue (est. $1.5B); FY revenue guidance of $5.2B–$5.3B against the $5.9B consensus.
−0.1% · S&P 500 −0.4%
Where it ended: a close of $114.63 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 9, 2027 (EPS est. $1.89, revenue est. $1.6B).
Nothing in the past 12 months.
All INCY dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for INCY and SPY from Benzinga historical bars. Not investment advice.